The cell lines were chosen based on key mutations driving lung cancer: EGFR, KRAS, and additionally TP53 mutation status, in order to evaluate whether lung cancer cell lines of different origin respond similarly to anticancer properties of RESV and whether there is any correlation between the mode of RESV action and the lung cancer cell type. Here, TP53 is linked to lung carcinoma.